Synovus Financial’s Integra LifeSciences IART Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-6,122
Closed -$217K 860
2024
Q1
$217K Buy
6,122
+467
+8% +$18.7K ﹤0.01% 799
2023
Q4
$246K Sell
5,655
-44
-0.8% -$1.73K ﹤0.01% 759
2023
Q3
$218K Buy
5,699
+26
+0.5% +$1.09K ﹤0.01% 783
2023
Q2
$233K Sell
5,673
-232
-4% -$11.2K ﹤0.01% 780
2023
Q1
$339K Sell
5,905
-915
-13% -$51.6K ﹤0.01% 695
2022
Q4
$382K Buy
6,820
+217
+3% +$11K ﹤0.01% 683
2022
Q3
$283K Sell
6,603
-491
-7% -$25.2K ﹤0.01% 721
2022
Q2
$376K Buy
7,094
+152
+2% +$9.13K ﹤0.01% 658
2022
Q1
$449K Buy
6,942
+4
+0.1% +$263 ﹤0.01% 649
2021
Q4
$457K Buy
6,938
+112
+2% +$7.58K ﹤0.01% 659
2021
Q3
$466K Sell
6,826
-3,087
-31% -$218K ﹤0.01% 622
2021
Q2
$678K Buy
9,913
+105
+1% +$7.42K 0.01% 536
2021
Q1
$677K Buy
9,808
+158
+2% +$10.7K 0.01% 485
2020
Q4
$628K Buy
9,650
+845
+10% +$45.5K 0.01% 495
2020
Q3
$417K Buy
8,805
+288
+3% +$13.7K 0.01% 536
2020
Q2
$400K Buy
8,517
+16
+0.2% +$786 0.01% 514
2020
Q1
$377K Buy
8,501
+454
+6% +$23.8K 0.01% 601
2019
Q4
$473K Sell
8,047
-1,125
-12% -$67K 0.01% 482
2019
Q3
$553K Buy
+9,172
New +$546K 0.01% 436

Other funds holding IART

Synovus Financial's IART Position: Q2 2024 in Review

Synovus Financial sold out of Integra LifeSciences (IART) in Q2 2024, closing a stake of 6,122 shares — an estimated $217K sold.

Synovus Financial first reported a position in IART in Q3 2019 and held it in 19 quarters. The position peaked at $678K in Q2 2021. 238 funds tracked by Wall St. Rank hold IART as of Q2 2024.

  • Synovus Financial reported no remaining Integra LifeSciences position as of Q2 2024 after selling out during the quarter.
  • Synovus Financial sold 6,122 Integra LifeSciences shares in Q2 2024, an estimated $217K.
  • Synovus Financial first reported a position in Integra LifeSciences in Q3 2019 and held it in 19 quarters.
  • Synovus Financial's Integra LifeSciences position peaked at $678K in Q2 2021.
  • 238 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2024.

Based on Synovus Financial's 13F filing for Q2 2024, filed 13 Aug 2024.